![Rahul Banerjee: Chronicle disparities in Relapsed or Refractory myeloma and why they matter](https://oncodaily.com/pub/uploads/2024/07/wQKT48LX_400x400-e1720968155229.png)
Rahul Banerjee: Chronicle disparities in Relapsed or Refractory myeloma and why they matter
Rahul Banerjee shared on X:
“Now in Blood Cancer Journal – our work to chronicle disparities specifically in Relapsed or Refractory myeloma and why they matter.
Trial-studied vs optimal drug dosing
Racial and socioeconomic gaps re: CAR-T and bsAbs
Multiple Myeloma supportive care, inc PCP access, and more
Disparities are well documented in myeloma, particularly re: diagnosis, time to Treatments initiation, access to ASCT. But many unique factors arise at relapse that make the landscape of great R/R Multiple Myeloma treatment options harder to traverse for some patients than others. Examples below.
![Rahul Banerjee: Chronicle disparities in Relapsed or Refractory myeloma and why they matter 2 Rahul Banerjee](https://oncodaily.com/pub/uploads/2024/09/GWJoNYNXoAAKENn-800x434.jpeg)
One problem to highlight: The stubborn disconnect between drug dosing in initial trials vs optimized strategies we’ve discovered thereafter to high PFS and low tox. Not just myeloma trivia for fellows… important to ensure there aren’t 2 standards of care for Multiple Myeloma treatment.
Our list of potential solutions to lower disparities in relapsed/refractory myeloma: Note the large emphasis on this being a team sport. Primary oncologists and MM specialists and PCPs all are integral parts of this team, and we need ways to improve access to all of them.
Plus organizations that offer -based hotlines for patients and caregivers to get help with finding a MM specialist, understanding Treatments, and more. I’ll be making an EMR dotphrase!
Thanks International Myeloma Foundation, The Multiple Myeloma Research Foundation, The Leukemia and Lymphoma Society, HealthTree Foundation, Cancer Support Community and others for offering these!
Limitations of our review include emphasis on USA patients living with myeloma, when in reality the biggest gaps between ‘haves’ and ‘have-nots’ in MM fall across international lines. And other disparities: language status, caregiver status, and intersectionality of them all.
Thanks Blood Cancer Journal and reviewers for excellent feedback and i3 Health for convening our interdisciplinary task force.
I learned so much from Craig Cole, Beth Faiman, Shonali Midha, Sikander Ailawadhi and of course the inimitable Yelak Biru who helped ground us all!”
Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel
Authors: Rahul Banerjee, Yelak Biru, Craig E. Cole, Beth Faiman, Shonali Midha and Sikander Ailawadhi
Source: Rahul Banerjee/X
For more posts by Rahul Banerjee, visit oncodaily.com
Rahul Banerjee is an assistant professor at Fred Hutchinson Cancer Center at the University of Washington. He completed his residency from the University of Pennsylvania health system. He completed his fellowship in haematology and oncology from University of California, San Francisco. He has authored over 70-peer reviewed publications. His clinical interests include multiple myeloma.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023